Stockscreener 앱 받기
1.08
1.83%
-0.01
전일 마감가:
$1.09
열려 있는:
$1.105
하루 거래량:
215.48K
Relative Volume:
0.04
시가총액:
$241.80M
수익:
$116.33M
순이익/손실:
$-209.25M
주가수익비율:
-0.5094
EPS:
-2.12
순현금흐름:
$-135.49M
1주 성능:
-11.57%
1개월 성능:
+33.45%
6개월 성능:
-50.46%
1년 성능:
-60.66%
1일 변동 폭
$1.065
$1.105
1주일 범위
$1.065
$1.22
52주 변동 폭
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
명칭
Esperion Therapeutics Inc
전화
734-887-3903
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.08 | 241.80M | 116.33M | -209.25M | -135.49M | -2.12 |
|
RGC
Regencell Bioscience Holdings Ltd
|
64.41 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
156.50 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.47 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-18 | 개시 | Goldman | Neutral |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-01 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2023-03-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-03-16 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 재개 | BofA Securities | Neutral |
| 2023-02-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 개시 | H.C. Wainwright | Buy |
| 2021-10-19 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-09 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 재개 | JP Morgan | Underweight |
| 2020-08-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 재개 | BofA/Merrill | Buy |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-16 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-03-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 재확인 | Needham | Strong Buy |
| 2018-12-13 | 개시 | Goldman | Sell |
| 2018-10-29 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-07-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-05-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
모두보기
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha
Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada
ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World
Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - marketscreener.com
Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance
Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa
Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia
ProShare Advisors LLC Boosts Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion settles patent case with Hetero USA over cholesterol drug By Investing.com - Investing.com South Africa
Esperion settles patent case with Hetero USA over cholesterol drug - Investing.com
Esperion reaches settlement agreement with Hetero USA, affiliates - TipRanks
Esperion (ESPR) Reaches Settlement to Protect NEXLETOL Patents | ESPR Stock News - GuruFocus
Esperion Reaches Settlement Agreement with Second ANDA - GlobeNewswire
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Manila Times
Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory - Stock Titan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DE - Defense World
Deutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Zacks Research Has Pessimistic Outlook of ESPR Q2 Earnings - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLC - Defense World
Zacks Research Has Positive Outlook of ESPR FY2027 Earnings - Defense World
BNP Paribas Financial Markets Has $337,000 Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
D. E. Shaw & Co. Inc. Grows Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Northern Trust Corp Buys 65,662 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion Therapeutics discovers new ATP citrate lyase inhibitors - BioWorld MedTech
Esperion to Participate in Upcoming June Investor Conferences - GlobeNewswire
Esperion at H.C. Wainwright Conference: Strategic Growth and Future Plans - Investing.com
Esperion to Present Latest Cardiovascular Drug Developments at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Average Target Price from Brokerages - Defense World
Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival - insights.citeline.com
Raymond James Financial Inc. Invests $98,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute - marketscreener.com
Esperion reaches settlement agreement with Micro Labs - TipRanks
Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol - Nasdaq
Esperion (ESPR) Reaches Settlement with Micro Labs Over Patent Dispute | ESPR Stock News - GuruFocus
Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol - marketscreener.com
Esperion Settles Patent Litigation with Micro Labs Regarding NEXLETOL Generic Marketing Rights - Nasdaq
Esperion Reaches Settlement Agreement with ANDA Filer Not - GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - Stock Titan
Cantor Fitzgerald Has Negative View of ESPR FY2025 Earnings - Defense World
Needham & Company LLC Cuts Esperion Therapeutics (NASDAQ:ESPR) Price Target to $4.00 - Defense World
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - Yahoo Finance
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Esperion at The Citizens JMP Life Sciences Conference: Strategic Growth Insights - Investing.com India
Esperion Therapeutics Inc (ESPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.17%
자본화:
|
볼륨(24시간):